Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.
Cidara Therapeutics, Inc. (CDTX) generates news primarily as a clinical-stage biotechnology company developing drug-Fc conjugate (DFC) therapeutics through its proprietary Cloudbreak platform. Most recent coverage focuses on CD388, a long-acting antiviral DFC designed as a non-vaccine preventative for seasonal and pandemic influenza, as well as on corporate transactions and government collaborations.
News about Cidara frequently highlights clinical trial milestones for CD388. This includes updates on the Phase 2b NAVIGATE trial in healthy unvaccinated adults and the Phase 3 ANCHOR trial in adults and adolescents at higher risk of influenza complications, including individuals with immune-compromised conditions, certain comorbidities, and adults over 65 years of age. Articles often describe trial design, enrollment progress, interim analysis plans, and safety and efficacy results reported by the company.
Investors following CDTX news will also see disclosures on regulatory interactions and designations, such as Fast Track and Breakthrough Therapy designations granted by the U.S. Food and Drug Administration (FDA) for CD388, and company commentary on plans to seek biologics license application (BLA) approval based on a single Phase 3 study. Additional coverage includes Cidara’s BARDA agreement to support expanded manufacturing and clinical development of CD388, detailing federal funding for onshoring manufacturing and additional clinical and non-clinical work.
Another major theme in Cidara’s news flow is its acquisition by Merck. Releases describe Merck’s definitive agreement to acquire Cidara through a cash tender offer and subsequent merger, the tender offer terms, and Merck’s statements about integrating CD388 into its respiratory portfolio. Updates from Merck note the successful completion of the tender offer, the planned merger to make Cidara a wholly owned subsidiary, and the expected delisting of Cidara’s common stock from the Nasdaq Global Market.
On this CDTX news page, readers can review historical and transaction-related announcements, clinical data presentations at scientific conferences, investor conference participation, and quarterly corporate updates. For those researching Cidara’s development of CD388, its Cloudbreak platform, and the transition of Cidara into Merck’s portfolio, this news feed provides a centralized view of key public communications over time.
Cidara Therapeutics (Nasdaq: CDTX) reported its financial results for Q2 2020, highlighting significant corporate developments. The company successfully dosed the first patient in its Phase 3 ReSPECT trial for rezafungin, aimed at preventing invasive fungal disease in patients undergoing blood and marrow transplantation. Financially, Cidara had $64.1 million in cash as of June 30, 2020, with increased R&D expenses of $17.6 million due to clinical trial costs. The net loss for Q2 2020 was $18.3 million, compared to $13.5 million in Q2 2019.
Cidara Therapeutics (Nasdaq: CDTX) announced that its CEO, Jeffrey Stein, Ph.D., will join the B. Riley FBR Virtual Summer Series panel on antiviral therapeutics on July 21, 2020, at 1:00 PM ET / 10:00 AM PT. The panel will focus on new approaches in the field of antiviral treatment. Cidara is dedicated to developing long-acting therapeutics to enhance care for patients with serious fungal and viral infections, notably through its lead antifungal candidate, rezafungin, and its Cloudbreak® antiviral platform.
Cidara Therapeutics (Nasdaq: CDTX) announced that CEO Jeffrey Stein will participate in the Cantor Fitzgerald Virtual Symposium on June 30, 2020. The event will focus on innovative approaches to treating infections, including COVID-19, and discuss the importance of stockpiling in the U.S. Cidara is working on groundbreaking therapies to improve care for severe fungal and viral infections, including its lead candidate, rezafungin, and antiviral platform Cloudbreak®. The announcement highlights the company's commitment to addressing critical health challenges.
Cidara Therapeutics (Nasdaq: CDTX) has announced that its CEO, Jeffrey Stein, Ph.D., will present virtually at the Raymond James Human Health Innovations Conference on June 18, 2020, at 3:40 PM ET. The company focuses on developing long-acting therapeutic solutions for serious fungal and viral infections. Notably, Cidara is advancing its lead Phase 3 antifungal candidate, rezafungin, along with antiviral conjugates from its Cloudbreak antiviral platform. Investors can access the live webcast on the company's website.
Cidara Therapeutics has commenced the ReSPECT pivotal Phase 3 clinical trial to evaluate the efficacy and safety of its antifungal candidate, rezafungin, for preventing invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is designed for once-weekly administration, potentially simplifying complex treatment regimens. The trial aims to enroll approximately 462 adults and will compare rezafungin to standard daily antifungal therapies. Successful outcomes may position rezafungin as a new standard of care.
Cidara Therapeutics (Nasdaq: CDTX) reported financial results for Q1 2020, with a net loss of $14.5 million, an improvement from $16.6 million in Q1 2019. Cash and equivalents increased to $74.3 million. The company activated its first clinical site for the Phase 3 ReSPECT trial of rezafungin, focused on preventing invasive fungal disease in bone marrow transplant patients. However, guidance on the ongoing ReSTORE trial's top-line data is suspended amid COVID-19 uncertainties. Cidara is also exploring funding for COVID-19-related clinical trials.